Immune checkpoint inhibitors before high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed and refractory classical Hodgkin lymphoma

Mochkin N.E., Melnichenko V.Yа., Protopopova Yu.V.

Classical Hodgkin lymphoma is considered a potentially curable cancer, however, relapsed and refractory disease is observed in approximately 10–30% of patients after the first-line treatment. The choice of further therapy approach is complex because efficacy of traditional second-line chemotherapy regimens is limited. Immune checkpoint inhibitors (PD-1-inhibitors) are a highly effective option in relapses and refractory classical Hodgkin lymphoma at present. This article presents a comprehensive review of studies demonstrating feasibility and safety of PD-1-inhibitors as a bridge for autologous stem cell transplantation, enabling to achieve a durable response to treatment.

1. Connors JM. Hodgkin’s Lymphoma: The Hazards of Success. J Clin Oncol. 2003; 21(18): 3388-90. doi: 10.1200/JCO.2003.07.001.

2. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27(27): 4548-54. doi: 10.1200/JCO.2008.19.8820.

3. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. N Engl J Med. 2015; 372(17): 1598-607. doi: 10.1056/ NEJMoa1408648.

4. Montanari F, Diefenbach C. Relapsed Hodgkin lymphoma: management strategies. Curr Hematol Malig Rep. 2014; 9(3): 284-93. doi: 10.1007/ s11899-014-0220-7.

5. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23): 4934-7. doi: 10.1182/blood-2010-05-282756.

6. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, et al. ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin’s Disease. Blood. 1999; 93(11): 3632-6. doi: 10.1182/blood.V93.11.3632.

7. Aparicio J, Segura A, Garcerá S, Oltra A, Santaballa A, Yuste A, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999; 10(5): 593-5. doi: 10.1023/a:1026454831340.

8. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97(3): 616-23. doi: 10.1182/blood.V97.3.616.

9. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002; 13(10): 1628-35. doi: 10.1093/annonc/mdf221.

10. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003; 14(12): 1762-7. doi: 10.1093/annonc/mdg496.

11. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, et al. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin’s Lymphoma. J Clin Oncol. 2010; 28(34): 5074-80. doi: 10.1200/JCO. 2010.30.5771.

12. Labrador J, Cabrero-Calvo M, Pérez-López E, Mateos MV, Vázquez L, Caballero MD, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol. 2014; 93(10): 1745-53. doi: 10.1007/s00277-014-2114-0.

13. Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016; 34(27): 3293-9. doi: 10.1200/JCO.2016.66.4466.

14. Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016; 34(23): 2690-7. doi: 10.1200/JCO.2016.66.4482.

15. Meti N, Esfahani K, Johnson N. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers. 2018; 10(6): 204. doi: 10.3390/cancers10060204.

16. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008; 26(1): 677-704. doi: 10.1146/annurev.immunol.26.021607.090331.

17. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14): 1428-39. doi: 10.1200/JCO.2017.76.0793.

18. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015; 372(4): 311-9. doi: 10.1056/NEJMoa1411087.

19. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019; 134(14): 1144–53. doi: 10.1182/blood. 2019000324.

20. Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023; 142(10): 878-86. doi: 10.1182/blood.2022019386.

21. Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023; 7(20): 6266-74. doi: 10.1182/bloodadvances.2023010334.

22. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, et al. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. The Oncologist. 2020; 25(10): 878-85. doi: 10.1634/theoncologist.2020-0167.

23. Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, et al. Chemotherapy after PD- 1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. Br J Haematol. 2022; 198(1): 82-92. doi: 10.1111/bjh.18183.

24. Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, et al. Efficacy of chemotherapy or chemo- anti- PD- 1 combination after failed anti- PD- 1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. Am J Hematol. 2018; 93(8): 1042-9. doi: 10.1002/ajh.25154.

25. Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, et al. Effectiveness of chemotherapy after anti- PD- 1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med. 2020; 9(21): 7830-6. doi: 10.1002/cam4.3262.

26. Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, et al. Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. Br J Haematol. 2022; 198(1): 82-92. doi: 10.1111/bjh.18183.

27. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, et al. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. The Oncologist. 2020; 25(10): 878-85. doi: 10.1634/theoncologist.2020-0167.

28. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity. Clin Cancer Res. 2005; 11(18): 6713-21. doi: 10.1158/1078-0432.CCR-05-0883.

29. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004; 34(2): 336-44. doi: 10.1002/eji.200324181.

30. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013; 62(2): 203-16. doi: 10.1007/ s00262-012-1388-0.

31. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013; 62(3): 405-10. doi: 10.1007/s00262-012-1390-6.

32. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021; 5(6): 1648-59. doi: 10.1182/bloodadvances.2020003556.

33. Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25): 3605-16. doi: 10.1182/blood.2022015423.

34. Mamedova AA, Mochkin NE, Sarzhevskiy VO, Demina EA, Bogatyrev VS, Spornik AA, et al. Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin’s lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results). Oncohematology. 2022; 17(3): 40-47. (In Russ.) doi: 10.17650/1818-8346-2022-17-3-40-47.

35. Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, et al. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023; 9(5): 683-91. doi: 10.1001/jamaoncol.2022.7975.

36. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021; 39(28): 3109-17. doi: 10.1200/JCO.21.01056.

37. Mangasarova YK, Moiseeva TN, Margolin OV, Gorenkova LG, et al. Nivo-BeGEV as Preparation for Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Study. Clinical Oncohematology. 2023; 16(3): 280-286. (In Russ.) doi: 10.21320/2500-2139-2023-16-3-280-286.

38. Sarzhevskiy VO, Mamedova AA, Mochkin NE, Demina EA, et al. Nivo-DHAP Combined with Subsequent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Trial (ClinicalTrials.gov, NCT04091490). Clinical Oncohematology. 2024; 17(1): 1-10. (In Russ.) doi: 10.21320/2500-2139-2024-17-1-1-10.

39. Mochkin N, Sarzhevskiy V, Protopopova Y, Demina E, et al. P1091: Feasibility of ASCT after ANTI-PD-1 therapy for R/R classical Hodgkin lymphoma. HemaSphere [Internet]. 2022; 6 [URL].

40. Park JJ, Lin J, Huang E, Schaar DG. The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2021; 21(9): e726-30. doi: 10.1016/j.clml.2021.05.006.

41. Bai B, Wang XX, Gao Y, Li PF, He HX, Ping LQ, et al. Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2021; 56(5): 1151-8. doi: 10.1038/ s41409-020-01164-y.

42. Samara Y, Mei M. Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies. Cancers. 2022; 14(7): 1738. doi: 10.3390/cancers14071738.